Breast-cancer patients were divided based on their breast cancer pathology into either epidermal growth factor receptor 2 (HER2)-negative tumors, HER2+ tumors, or triple-negative tumor types. The dietary intake of the patients was evaluated for the previous five years using a 117-item semiquantitative food frequency questionnaire. This evidence concerns the gene ERBB2 and breast cancer.